Ubs Asset Management Americas Inc Aerie Pharmaceuticals Inc Transaction History

Ubs Asset Management Americas Inc

$381 Billion
Q3 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$6.37 - $15.23 $14,714 - $35,181	2,310 Added 4.51%	53,554 $810,000
Q2 2022 Aug 12, 2022	SELL	$4.95 - $9.16 $17,567 - $32,508	-3,549 Reduced 6.48%	51,244 $384,000
Q3 2021 Nov 15, 2021	BUY	$11.32 - $16.63 $758 - $1,114	67 Added 0.12%	54,793 $624,000
Q2 2021 Aug 16, 2021	BUY	$15.16 - $18.97 $191,774 - $239,970	12,650 Added 30.06%	54,726 $876,000
Q3 2020 Nov 13, 2020	SELL	$10.46 - $14.46 $12,217 - $16,889	-1,168 Reduced 2.7%	42,076 $495,000
Q2 2020 Aug 14, 2020	BUY	$12.0 - $16.13 $18,264 - $24,549	1,522 Added 3.65%	43,244 $638,000
Q1 2020 May 15, 2020	BUY	$11.84 - $25.52 $42,458 - $91,514	3,586 Added 9.4%	41,722 $563,000
Q4 2019 Feb 14, 2020	BUY	$17.72 - $25.1 $134,229 - $190,132	7,575 Added 24.79%	38,136 $921,000
Q3 2019 Nov 14, 2019	BUY	$18.41 - $28.0 $68,098 - $103,572	3,699 Added 13.77%	30,561 $587,000
Q2 2019 Aug 15, 2019	SELL	$28.97 - $48.21 $124,049 - $206,435	-4,282 Reduced 13.75%	26,862 $0
Q1 2019 May 14, 2019	SELL	$36.32 - $49.25 $2.63 Million - $3.57 Million	-72,404 Reduced 69.92%	31,144 $0
Q4 2018 Feb 13, 2019	SELL	$33.0 - $60.04 $53,196 - $96,784	-1,612 Reduced 1.53%	103,548 $3.74 Million
Q3 2018 Nov 14, 2018	BUY	$56.15 - $73.9 $310,846 - $409,110	5,536 Added 5.56%	105,160 $0
Q2 2018 Aug 14, 2018	SELL	$47.85 - $70.45 $469,791 - $691,678	-9,818 Reduced 8.97%	99,624 $0
Q1 2018 May 14, 2018	SELL	$51.15 - $61.0 $274,726 - $327,631	-5,371 Reduced 4.68%	109,442 $0
Q4 2017 Feb 09, 2018	BUY	$50.85 - $65.1 $3.77 Million - $4.83 Million	74,130 Added 182.21%	114,813 $0
Q3 2017 Nov 13, 2017	BUY	$48.6 - $60.1 $1.98 Million - $2.45 Million	40,683	40,683 $0

Others Institutions Holding AERI

# of Institutions

Shares Held

2.4M

Call Options Held

Put Options Held

View Full List

About AERIE PHARMACEUTICALS INC

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

More about AERI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.

Account